KODIAK SCIENCES INC. Research and Development Expense
KODIAK SCIENCES INC. (KOD) reported Research and Development Expense of $56.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- KODIAK SCIENCES INC. research and development expense for the quarter ending 2026-06-30 was $56.08M, a 31.16% increase year-over-year.
- KODIAK SCIENCES INC. research and development expense for the quarter ending 2026-03-31 was $48.55M, a 11.23% increase year-over-year.
- KODIAK SCIENCES INC. research and development expense for the quarter ending 2025-12-31 was $45.49M, a 43.19% increase year-over-year.
- KODIAK SCIENCES INC. research and development expense for the quarter ending 2025-09-30 was $50.48M, a 58.34% increase year-over-year.
- KODIAK SCIENCES INC. research and development expense for fiscal 2025 was $182.37M, a 44.63% increase from fiscal 2024.
- KODIAK SCIENCES INC. research and development expense for fiscal 2024 was $126.09M, a 38.88% decline from fiscal 2023.
- KODIAK SCIENCES INC. research and development expense for fiscal 2023 was $206.30M, a 22.91% decline from fiscal 2022.
- KODIAK SCIENCES INC. research and development expense for fiscal 2022 was $267.59M, a 23.12% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $56.08M 10-Q · filed 2026-08-13 | $104.63M 10-Q · filed 2026-08-13 | $150.12M derived: sum of 3 quarters · filed 2026-08-13 | $200.60M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $48.55M 10-Q · filed 2026-05-07 | $94.04M derived: sum of 2 quarters · filed 2026-05-07 | $144.52M derived: sum of 3 quarters · filed 2026-05-07 | $187.28M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $45.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $95.97M derived: sum of 2 quarters · filed 2026-03-31 | $138.73M derived: sum of 3 quarters · filed 2026-08-13 | $182.37M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $50.48M 10-Q · filed 2025-11-13 | $93.24M derived: sum of 2 quarters · filed 2026-08-13 | $136.88M 10-Q · filed 2025-11-13 | $168.65M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $42.76M 10-Q · filed 2026-08-13 | $86.40M 10-Q · filed 2026-08-13 | $118.18M derived: sum of 3 quarters · filed 2026-08-13 | $150.05M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $43.64M 10-Q · filed 2026-05-07 | $75.42M derived: sum of 2 quarters · filed 2026-05-07 | $107.29M derived: sum of 3 quarters · filed 2026-05-07 | $139.81M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $31.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $63.65M derived: sum of 2 quarters · filed 2026-03-31 | $96.16M derived: sum of 3 quarters · filed 2026-03-31 | $126.09M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $31.88M 10-Q · filed 2025-11-13 | $64.39M derived: sum of 2 quarters · filed 2025-11-13 | $94.32M 10-Q · filed 2025-11-13 | $140.95M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-06-30 | $32.51M 10-Q · filed 2025-08-13 | $62.45M 10-Q · filed 2025-08-13 | $109.07M derived: sum of 3 quarters · filed 2026-03-31 | $145.26M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-03-31 | $29.93M 10-Q · filed 2025-05-14 | $76.56M derived: sum of 2 quarters · filed 2026-03-31 | $112.75M derived: sum of 3 quarters · filed 2026-03-31 | $179.71M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2023-12-31 | $46.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $82.82M derived: sum of 2 quarters · filed 2026-03-31 | $149.78M derived: sum of 3 quarters · filed 2026-03-31 | $206.30M 10-K · filed 2026-03-31 | ||
| 2023-09-30 | $36.19M 10-Q · filed 2024-11-14 | $103.15M derived: sum of 2 quarters · filed 2024-11-14 | $159.67M 10-Q · filed 2024-11-14 | $215.66M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2023-06-30 | $66.96M 10-Q · filed 2024-08-14 | $123.48M 10-Q · filed 2024-08-14 | $179.47M derived: sum of 3 quarters · filed 2025-03-27 | $241.15M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2023-03-31 | $56.52M 10-Q · filed 2024-05-15 | $112.51M derived: sum of 2 quarters · filed 2025-03-27 | $174.19M derived: sum of 3 quarters · filed 2025-03-27 | $247.93M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2022-12-31 | $55.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $117.67M derived: sum of 2 quarters · filed 2025-03-27 | $191.41M derived: sum of 3 quarters · filed 2025-03-27 | $267.59M 10-K · filed 2025-03-27 | ||
| 2022-09-30 | $61.68M 10-Q · filed 2023-11-14 | $135.42M derived: sum of 2 quarters · filed 2023-11-14 | $211.60M 10-Q · filed 2023-11-14 | $287.19M derived: sum of 4 quarters · filed 2024-03-28 | ||
| 2022-06-30 | $73.74M 10-Q · filed 2023-08-14 | $149.92M 10-Q · filed 2023-08-14 | $225.52M derived: sum of 3 quarters · filed 2024-03-28 | $281.52M derived: sum of 4 quarters · filed 2024-03-28 | ||
| 2022-03-31 | $76.18M 10-Q · filed 2023-05-15 | $151.77M derived: sum of 2 quarters · filed 2024-03-28 | $207.78M derived: sum of 3 quarters · filed 2024-03-28 | $253.18M derived: sum of 4 quarters · filed 2024-03-28 | ||
| 2021-12-31 | $75.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $131.60M derived: sum of 2 quarters · filed 2024-03-28 | $177.00M derived: sum of 3 quarters · filed 2024-03-28 | $217.34M 10-K · filed 2024-03-28 | ||
| 2021-09-30 | $56.00M 10-Q · filed 2022-11-09 | $101.41M derived: sum of 2 quarters · filed 2022-11-09 | $141.74M 10-Q · filed 2022-11-09 | $179.10M derived: sum of 4 quarters · filed 2023-03-28 | ||
| 2021-06-30 | $45.40M 10-Q · filed 2022-08-09 | $85.74M 10-Q · filed 2022-08-09 | $123.10M derived: sum of 3 quarters · filed 2023-03-28 | $152.40M derived: sum of 4 quarters · filed 2023-03-28 | ||
| 2021-03-31 | $40.34M 10-Q · filed 2022-05-10 | $77.69M derived: sum of 2 quarters · filed 2023-03-28 | $107.00M derived: sum of 3 quarters · filed 2023-03-28 | $127.56M derived: sum of 4 quarters · filed 2023-03-28 | ||
| 2020-12-31 | $37.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $66.66M derived: sum of 2 quarters · filed 2023-03-28 | $87.22M derived: sum of 3 quarters · filed 2023-03-28 | $107.39M 10-K · filed 2023-03-28 | ||
| 2020-09-30 | $29.31M 10-Q · filed 2021-11-09 | $49.86M derived: sum of 2 quarters · filed 2021-11-09 | $70.03M 10-Q · filed 2021-11-09 | $82.86M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $20.56M 10-Q · filed 2021-08-09 | $40.73M 10-Q · filed 2021-08-09 | $53.56M derived: sum of 3 quarters · filed 2022-03-01 | $63.67M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $20.17M 10-Q · filed 2021-05-10 | $33.00M derived: sum of 2 quarters · filed 2022-03-01 | $43.12M derived: sum of 3 quarters · filed 2022-03-01 | $51.95M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $12.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $22.95M derived: sum of 2 quarters · filed 2022-03-01 | $31.78M derived: sum of 3 quarters · filed 2022-03-01 | $37.51M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $10.12M 10-Q · filed 2020-11-09 | $18.95M derived: sum of 2 quarters · filed 2020-11-09 | $24.68M 10-Q · filed 2020-11-09 | $31.53M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $8.84M 10-Q · filed 2020-08-10 | $14.56M 10-Q · filed 2020-08-10 | $21.41M derived: sum of 3 quarters · filed 2021-03-01 | $26.12M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | $5.72M 10-Q · filed 2020-05-11 | $12.57M derived: sum of 2 quarters · filed 2021-03-01 | $17.28M derived: sum of 3 quarters · filed 2021-03-01 | $20.87M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $6.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $11.56M derived: sum of 2 quarters · filed 2021-03-01 | $15.15M derived: sum of 3 quarters · filed 2021-03-01 | $18.79M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $4.71M 10-Q · filed 2019-11-12 | $4.71K 10-Q · filed 2018-11-16 | $8.30M derived: sum of 2 quarters · filed 2019-11-12 | $11.94M 10-Q · filed 2019-11-12 | $11.94K 10-Q · filed 2018-11-16 | $33.95M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $3.59M 10-Q · filed 2019-08-14 | $7.23M 10-Q · filed 2019-08-14 | $29.24M derived: sum of 3 quarters · filed 2020-03-16 | $29.24M derived: sum of 4 quarters · filed 2020-03-16 | ||
| 2018-03-31 | $3.64M 10-Q · filed 2019-05-15 | $25.65M derived: sum of 2 quarters · filed 2020-03-16 | $25.65M derived: sum of 3 quarters · filed 2020-03-16 | |||
| 2017-12-31 | $22.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $22.01M derived: sum of 2 quarters · filed 2020-03-16 | $22.02M 10-K · filed 2020-03-16 | |||
| 2017-09-30 | $3.15K 10-Q · filed 2018-11-16 | $13.25K 10-Q · filed 2018-11-16 | ||||
| 2016-12-31 | $14.05M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |